Citations

Showing 10 of 108135 citations.

Imaging features of adenosquamous carcinoma of the breast – A rare variant of metaplastic breast carcinoma
Sae-Kho, Tiffany Marian, Bhatt, Asha A. , Solanki, Malvika , Jeans, Elizabeth B. , Corbin, Kimberly S. , Fazzio, Robert T. , Glazebrook, Katrina N. , Bhatt, Asha, Solanki, Malvika H, Sae-Kho, Tiffany M.

Mayo Clinic

BJR|case reports | September 19, 2021 | Volume: 7 | Issue: 6 | Pages: No page available

10.1259/bjrcr.20210108 | PMID 35300231 Get It

Adenosquamous carcinoma of the breast is a rare subtype of metaplastic carcinoma, which accounts for <1% of invasive breast malignancy. Metaplastic carcinoma is usually high grade and aggressive with typically reported benign imaging features when compared to invasive ductal carcinoma. However, the adenosquamous variant is a subtype with a more favorable prognosis. Within the literature, there is limited imaging description with case studies focusing on metaplastic carcinoma. Herein, we report seven cases of the adenosquamous subtype describing the imaging findings with correlation to clinical history and pathology. The majority of patients (n = 6) presented with palpable breast masses. One patient was identified through screening mammography. Mammographically (n = 6), tumors appeared as irregular masses. Sonographically (n = 7), tumors appeared as irregular masses ranging from solid to mixed solid/cystic masses. On MRI (n = 1), one tumor appeared as an irregular rim enhancing mass. FDG PET/CT (n = 2) and whole-body bone scan (n = 1) were also available for review. The majority of tumors were low-grade (n = 6) with only one high-grade tumor. This case series of seven patients demonstrated predominantly suspicious imaging features despite the majority being low-grade tumors.
Histologic Analysis of Urethral Stricture in 9 Patients Following Dorsal Vaginal Graft Urethroplasty
Pathak, Ram A. , Geiger, Xochiquetzal J., Ericson, Christian , Wilson, Robert R. , Petrou, Steven P. , Geiger, Xochiquetzal, Wilson, Robert R A

Mayo Clinic

American Journal of Clinical Pathology | September 19, 2021 | Volume: 157 | Issue: 5 | Pages: 742-747

10.1093/ajcp/aqab183 | PMID 34724532 Get It

Abstract Objective To present the pathologic analysis of female urethral strictures obtained during reconstructive urethroplasty. Methods Nine separate female urethral tissue specimens were obtained during dorsal vaginal graft urethroplasty by a single surgeon (S.P.P.). Samples were serially sectioned and fixed in 10% formalin 6 to 12 hours before routine processing in paraffin blocks. Serial 5-µm sections were subjected to H&E, Masson trichrome, and elastin staining. End point analysis included evaluation for epithelial hyperplasia and cell type, mucosal edema, degree of fibroblast/inflammatory cell infiltrate, and elastin fiber density and distribution. Results Nine specimens were examined. Six specimens had epithelial linings of stratified squamous epithelium overlying fibrosis (67%), 1 had mixed squamous and urothelial epithelium, and 2 had only urothelial epithelium. Two specimens (29%) showed acute injury with prominent squamous papillary hyperplasia, focal erosion, and patchy mucosal hemorrhage. Areas of urethral stricture were variably thickened, with increased, densely packed collagen fibers and associated mucosal lymphocytic inflammation ranging from mild and patchy to focally dense with lymphoid aggregates. The highest elastin fiber density appeared to be associated with vessels and overlying muscle bundles in the submucosa. Conclusions Further elucidation of histopathologic characteristics may illuminate more appropriate therapeutic pathways for female urethral stricture disease management.
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases
Ginès, Pere , Lammert, Frank , Graupera, Isabel , Serra‐Burriel, Miquel , Allen, Alina M. , Wong, Vincent Wai‐Sun , Thiele, Maja , Grgurević, Ivica , Augustín, Salvador , Tsochatzis, Emmanuel , Schattenberg, Jörn M. , Guha, Indra Neil , Martini, Andréa , Morillas, Rosa M. , Koning, Harry J. de , Pich, Judit, T., Ann , Díaz, M. A. Cruz , Newsome, Philip N. , Manns, Michael P. , Kamath, Patrick S. , Krag, Aleksander , Cervera, Marta , Allen, Alina M , Wong, Vincent Wai-Sun , de Knegt, Robert J , Tsochatzis, Emmanuel A , Schattenberg, Jörn M , Guha, Indra Neil , de Koning, Harry J , Fabrellas, Núria , Ma, Ann T , Newsome, Philip N , Krag, Aleksander , Gines, Pere , Thiele, Maja , Castera, Laurent , Hartmann, Phillipp , Caballería, Llorenç , Garcı́a-Retortillo, Montserrat , Fabrellas, Núria , Diaz, M. Alba, Roulot, Dominique M.

Mayo Clinic

Hepatology | September 19, 2021 | Volume: 75 | Issue: 1 | Pages: 219-228

10.1002/hep.32163 | PMID 34537988 Get It

Abstract Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non‐alcoholic fatty liver disease and alcohol‐related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. These modalities may be utilized for screening for liver fibrosis in at‐risk populations. Thus far, a limited number of population‐based studies using noninvasive tests in different areas of the world indicate that a significant percentage of subjects without known liver disease (around 5% in general populations and a higher rate −18% to 27%‐in populations with risk factors for liver disease) have significant undetected liver fibrosis or established cirrhosis. Larger international studies are required to show the harms and benefits before concluding that screening for liver fibrosis should be applied to populations at risk for chronic liver diseases. Screening for liver fibrosis has the potential for changing the current approach from diagnosing chronic liver diseases late when patients have already developed complications of cirrhosis to diagnosing liver fibrosis in asymptomatic subjects providing the opportunity of preventing disease progression.
Time-to-enrollment in clinical trials investigating neurological recovery in chronic spinal cord injury: observations from a systematic review and ClinicalTrials.gov database
Moinuddin, F. M. , Yolcu, Yagiz Ugur, Wahood, Waseem , Zreik, Jad, Goncalves, Sandy, Windebank, Anthony John, Qu, Wenchun , Bydon, Mohamad , Yolcu, Yagiz Ugur, Windebank, Anthony John

Mayo Clinic

Neural Regeneration Research | September 19, 2021 | Volume: 17 | Issue: 5 | Pages: 953-958

10.4103/1673-5374.324826 | PMID 34558507 Get It

Currently, large numbers of clinical trials are performed to investigate different forms of experimental therapy for patients suffering from chronic spinal cord injury (SCI). However, for the enrollment process, there are different views on how the time period between injury and interventions should be determined. Herein, we sought to evaluate the impact of time-to-enrollment in chronic SCI clinical trials. A data set comprising 957 clinical studies from clinicalTrials.gov was downloaded and analyzed focusing on the eligibility criteria for post-injury time-to-enrollment. We also aggregated individual patient data from nine clinical trials of regenerative interventions for chronic SCI selected by a systematic literature search from 1990 to 2018. Characteristics of the studies were assessed and compared by dividing into three groups based on time-to-enrollment (group 1 ≤ 12 months, group 2 = 12–23 months and group 3 ≥ 24 months). In ClinicalTrials.gov registry, 445 trials were identified for chronic SCI where 87% (385) were unrestricted in the maximum post-injury time for trial eligibility. From systematic literature search, nine studies and 156 patients (group 1 = 30, group 2 = 55 and group 3 = 71) were included. The range of time-to-enrollment was 0.5 to 321 months in those studies. We also observed various degrees of motor and sensory improvement in between three time-to-enrollment groups. Our results indicate that enrolling wide ranges of time-to-enrollment in a group may present imprecise outcomes. Clinical trial designs should consider appropriate post-injury time frames to evaluate therapeutic benefit.
The hemodynamic spectrum of pulmonary vein stenosis from fibrosing mediastinitis
Ingraham, Brenden , Packer, Douglas L. , Holmes, David R. , Reddy, Yogesh N.V. , Ingraham, Brenden S , Nishimura, Rick

Mayo Clinic

Catheterization and Cardiovascular Interventions | September 18, 2021 | Volume: 99 | Issue: 1 | Pages: 198-200

10.1002/ccd.29955 | PMID 34536328 Get It

AbstractA 63‐year‐old man presented with hemoptysis and progressive dyspnea. His echocardiogram was concerning for pulmonary hypertension (PH) and CT chest showed fibrosing mediastinitis with possible cardiac involvement. Right heart catheterization revealed PH at rest and worsened with exercise. CT findings and simultaneous measurement of pulmonary capillary wedge pressure (PCWP), left atrial pressure, and left ventricular pressure helped diagnose pulmonary vein (PV) stenosis as the etiology of his PH. Both upper pulmonary veins were stented, and repeat exercise hemodynamic study revealed a substantial reduction in pulmonary arterial pressure with improvement in subjective dyspnea, cardiac output reserve, mechanical efficiency, and ventilatory efficiency. Repeat right upper PCWP normalized, consistent with resolution of the PV stenosis.
Cardiac Risk Assessment in Liver Transplant Candidates: A Survey of National Practice Patterns
Barman, Pranab , Chadha, Ryan , VanWagner, Lisa B. , Barman, Pranab M, Chadha, Ryan , VanWagner, Lisa B

Mayo Clinic

Liver Transplantation | September 18, 2021 | Volume: 28 | Issue: 3 | Pages: 501-504

10.1002/lt.26307 | PMID 34536331 Get It

Longevity and subject‐reported satisfaction after minimally invasive jawline contouring
Müller, Daniel S. , Prinz, Valentina, Sulovsky, Monika , Cajkovsky, Mia, Cotofana, Sebastian , Frank, Konstantin , Müller, Daniel , Cotofana, Sebastian , Frank, Konstantin , Moellhoff, Nicholas

Mayo Clinic

Journal of Cosmetic Dermatology | September 18, 2021 | Volume: 21 | Issue: 1 | Pages: 199-206

10.1111/jocd.14410 | PMID 34536051 Get It

AbstractBackgroundMinimally invasive treatments as soft tissue filler injections can enhance the appearance of the jawline. This prospective, single‐center study investigated aesthetic outcome, patient satisfaction, adverse events, and volume changes after jawline contouring using standardized reporting scales and objectifiable 3D surface analysis.MethodsA total of 30 patients (1 male and 29 females, mean age: 57.2 (±8.7) years) were investigated. Patients underwent jawline augmentation using a highly cross‐linked hyaluronic acid–based soft tissue filler. Three‐dimensional surface imaging was performed after 2 weeks, and 3, 6, 9, and 12 months. Furthermore, the aesthetic results and the occurrence of complications were investigated after two weeks, and 3, 6, 9, and 12 months.ResultsThe surface‐volume coefficient (SVC) had an average of 1.10 ± 0.2 after 14 days, 0.95 ± 0.1 after 3 months, 0.83 ± 0.1 after 6 months, 0.74 ± 0.1 after 9 months, and 0.63 ± 0.1 after 12 months. A significant correlation was revealed between time of measurement and measured SVC with rp = −0.761, p < 0.001. Multivariate analysis revealed a significant difference between the measured SVC and the different time points of measurement with p < 0.001. The data revealed strong aesthetic improvement with results most often reported as “very much improved” according to the 5‐point GAIS after 3, 6, and 9 months, both by the investigator and by the patients. A 12‐month follow‐up analysis showed “much improved” results in a majority of cases.ConclusionThe result of this investigation showed that jawline enhancement using minimally invasive soft tissue filler injections produces durable, safe results that are generally rated as very satisfying from a patient's and investigator's perspective over a time period of 12 months.
Ultrasound Screening for Transplant Renal Artery Stenosis Risk Stratification Using Standardized Criteria in Structured Reporting: A Validation Study
Fananapazir, Ghaneh , LaRoy, Jennifer, Navarro, Shannon M. , Corwin, Michael T. , Carney, Benjamin W. , Troppmann, Christoph , Fananapazir, Ghaneh

Mayo Clinic

Journal of Ultrasound in Medicine | September 18, 2021 | Volume: 41 | Issue: 6 | Pages: 1433-1438

10.1002/jum.15826 | PMID 34536039 Get It

ObjectivesTo evaluate the effectiveness of templated ultrasound reports using transplant renal artery stenosis (TRAS) risk stratification (RS), particularly with regard to utilization of downstream angiographic studies and angiographic presence of TRAS.MethodsUltrasounds with TRAS‐RS templated reports from August 2017 to May 2020 were included. Studies were excluded if performed <28 days posttransplant and where TRAS was not clinically considered. A total of 530 ultrasounds met inclusion/exclusion criteria. TRAS‐RS criteria were recorded (renal artery velocity ≥300 cm/s, spectral broadening in the renal artery, and intraparenchymal acceleration time ≥0.1 second). Depending on the number of criteria present, recipients were stratified into low (0/3), intermediate (1/3), high (2/3), and very high (3/3) risk for TRAS. Student's t‐test was performed to identify whether the TRAS‐RS category was associated with 1) performance of angiography to assess for TRAS and 2) angiographic presence of TRAS.ResultsOf the 530 ultrasounds, 74 (14%) underwent angiography. Of these, 41 (55%) were positive for TRAS (overall positive rate, 8%). Number of ultrasounds, angiograms, and angiograms positive for TRAS, respectively, in each of the TRAS‐RS categories for the 530 cases were: low probability: n = 370 (70% of all studied reports), 7 angiograms (2%), and 0 (0%) positive for TRAS; intermediate: n = 87 (16%), 24 angiograms (28%), and 8 (33%) positive; high: n = 46 (9%), 23 angiograms (50%), and 14 (61%) positive; and very high: n = 27 (5%), 20 angiograms (74%), and 19 (95%) positive. TRAS‐RS score was associated with subsequent performance of angiography and positive rate for TRAS (P < .01).ConclusionImplementing a defined ultrasound screening tool with templated reporting for TRAS allowed for effective selection of those requiring an angiogram.
The peril and promise of sensitivity in eating disorders
Sim, Leslie , Peterson, Carol B.

Mayo Clinic

International Journal of Eating Disorders | September 18, 2021 | Volume: 54 | Issue: 11 | Pages: 2046-2056

10.1002/eat.23606 | PMID 34536033 Get It

AbstractDifferential susceptibility, a reconceptualization of the diathesis‐stress model of psychopathology, describes gene–environment interactions that reflect individual differences in responsiveness to environmental influences, both detrimental and beneficial. This model has been described metaphorically by the classification of orchids, which thrive under optimal care but wither under adverse conditions, and dandelions, which weather broad environmental circumstances but are less responsive to careful cultivation. Etiological research in the field of eating disorders has largely focused on the identification of specific behavioral phenotypes, temperamental traits, genotypes and neurobiological processes that confer risk. In this article, we propose that these putative vulnerability factors represent phenotypes and endophenotypes of a genetic predisposition towards environmental sensitivity. We assert that this sensitivity not only transmits eating disorder risk but also confers resilience, depending on the circumstances. In particular, we propose that differential susceptibility can be used as a framework to organize disparate temperamental and neurobiological findings and their complex interplay with various developmental, environmental and sociocultural influences to increase eating disorder risk and treatment responsiveness. Finally, we assert that viewed through the lens of differential susceptibility, sensitivity can be leveraged to refine our interventions and develop novel treatment and prevention strategies to support favorable outcomes for individuals with eating disorders.
Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee
Fung, Maxwell A. , Vidal, Claudia I. , Armbrecht, Eric A., Andea, Aleodor A. , Cassarino, David S. , Comfere, Nneka I. , Emanuel, Patrick O. , Ferringer, Tammie , Kim, Jinah , Lauer, Scott , Linos, Konstantinos , Missall, Tricia A. , Sundram, Uma , Panel, Rating, Calame, Antoanella , Duncan, Lyn M. , Elston, Dirk M. , Hosler, Gregory A. , Hurley, Yadira, Messina, Jane L. , Myles, Jonathan P. , Prieto, Víctor G. , Reddy, Vijaya , Schaffer, András , Subtil, Antonio , Fung, Maxwell A , Vidal, Claudia I , Cassarino, David S , Comfere, Nneka , Emanuel, Patrick O , Kim, Jinah , Linos, Konstantinos , Missall, Tricia A , Motaparthi, Kiran , Patel, Rajiv M , Sundram, Uma , Hosler, Gregory A , Hurley, Maria Yadira , Messina, Jane , Plaza, Jose Antonio , Prieto, Victor G , Subtil, Antonio , Hristov, Alexandra C. , Novoa, Roberto A. , Patel, Rajiv M. , Shalin, Sara C. , Panel, Rating, Bennett, Daniel D , Lazar, Alexander J. , Lowe, Lori , Myles, Jonathan

Mayo Clinic

Journal of Cutaneous Pathology | September 18, 2021 | Volume: 49 | Issue: 3 | Pages: 231-245

10.1111/cup.14135 | PMID 34536035 Get It

AbstractBackgroundAppropriate use criteria (AUC) provide patient‐centered physician guidance in test selection. An initial set of AUC was reported by the American Society of Dermatopathology (ASDP) in 2018. AUC reflect evidence collected at single timepoints and may be affected by evolving evidence and experience. The objective of this study was to update and expand AUC for selected tests.MethodsRAND/UCLA (RAND Corporation [Santa Monica, CA]/University of California Los Angeles) methodology used includes the following: (a) literature review; (b) review of previously rated tests and previously employed clinical scenarios; (c) selection of previously rated tests for new ratings; (d) development of new clinical scenarios; (e) selection of additional tests; (f) three rating rounds with feedback and group discussion after rounds 1 and 2.ResultsFor 220 clinical scenarios comprising lymphoproliferative (light chain clonality), melanocytic (comparative genomic hybridization, fluorescence in situ hybridization, reverse transcription polymerase chain reaction, telomerase reverse transcriptase promoter), vascular disorders (MYC), and inflammatory dermatoses (periodic acid‐Schiff, Gömöri methenamine silver), consensus by panel raters was reached in 172 of 220 (78%) scenarios, with 103 of 148 (70%) rated “usually appropriate” or “rarely appropriate” and 45 of 148 (30%), “appropriateness uncertain.” Limitations: The study design only measures appropriateness. Cost, availability, test comparison, and additional clinical considerations are not measured. The possibility that the findings of this study may be influenced by the inherent biases of the dermatopathologists involved in the study cannot be excluded.ConclusionsAUC are reported for selected diagnostic tests in clinical scenarios that occur in dermatopathology practice. Adhering to AUC may reduce inappropriate test utilization and improve healthcare delivery.